Several months ago, Eli Lilly (LLY) launched LisPro, an authorized generic version of its Humalog insulin at half price, or $137.35 a vial. The move was designed to defuse anger over the rising cost of insulin because LisPro would be more affordable to the uninsured or those with high-deductible insurance plans, whose copays are, typically, tied to list prices. But last month, a pair of U.S. senators issued a report saying the vast majority of pharmacies failed to offer LisPro and the effort was a bust. Lilly chief executive David Ricks called the findings “nonsense,” and argued the real access problem has been with middlemen — the pharmacy benefit managers — that prefer products with higher list prices because these offer higher rebates. We spoke with Mike Mason, who heads the Lilly diabetes business, at the J.P. Morgan Healthcare Conference about the limitations of this program. (The conversation was edited for length).

Pharmalot: What was the expectation when you launched the authorized generic?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy